Payment overview · 2025
General Payments
$487.52
16 reported records · 6 companies
Healthcare provider profile · identity verified
Humberto Simonetti, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PONCE, PR · NPI 1619972635
Verified facts
What the public records show
CMS Open Payments records show Humberto Simonetti, M.D. received $487.52 in general payments during 2025 across 16 reported records.
Boston Scientific Corporation accounted for 52.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $255.98 | 52.5% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$103.94 | 21.3% | 4 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $52.06 | 10.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.02 | 7.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.26 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.26 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.52 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $119.90 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $108.46 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $65.43 | 2 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PBG PUERTO RICO LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| ACUITY Steerable Normalized: acuity steerable |
Device | Boston Scientific Corporation | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 55 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1799 | 446 |
| Losartan Potassium | Losartan Potassium | 1302 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 1048 | 285 |
| Carvedilol | Carvedilol | 903 | 224 |
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 230 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 763 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 671 | 182 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 561 | 127 |
| Simvastatin | Simvastatin | 440 | 109 |
| Ezetimibe | Ezetimibe | 402 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 368 | 96 |
| Lisinopril | Lisinopril | 358 | 112 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 306 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 82 |
| Nifedipine Er | Nifedipine | 277 | 75 |
| Eliquis | Apixaban | 230 | 55 |
| Valsartan | Valsartan | 212 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 56 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 205 | 53 |
| Xarelto | Rivaroxaban | 205 | 39 |
| Gabapentin | Gabapentin | 203 | 61 |
| Furosemide | Furosemide | 187 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 49 |
| Synthroid | Levothyroxine Sodium | 176 | 43 |
| Famotidine | Famotidine | 171 | 47 |
| Metformin Hcl | Metformin Hcl | 164 | 41 |
| Irbesartan | Irbesartan | 161 | 39 |
| Atenolol | Atenolol | 157 | 40 |
| Omeprazole | Omeprazole | 141 | 40 |
| Fenofibrate | Fenofibrate | 137 | 35 |
| Meclizine Hcl | Meclizine Hcl | 132 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 123 | 40 |
| Spironolactone | Spironolactone | 121 | 23 |
| Entresto | Sacubitril/Valsartan | 115 | 26 |
| Candesartan Cilexetil | Candesartan Cilexetil | 94 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 21 |
| Allopurinol | Allopurinol | 89 | 26 |
| Flecainide Acetate | Flecainide Acetate | 79 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 20 |
| Sulindac | Sulindac | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 70 | 15 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 68 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 14 |
| Enalapril Maleate | Enalapril Maleate | 60 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 28 |
| Glimepiride | Glimepiride | 59 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 19 |
| Jardiance | Empagliflozin | 47 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 14 |
| Ramipril | Ramipril | 35 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 33 | suppressed |
| Opsumit | Macitentan | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.52 · 16 records | Boston Scientific Corporation | ACUITY Steerable, AVEIR, CAMZYOS, ELIQUIS, ENDURANT IIS, General - Therapies, LATITUDE Communicator Power Supply, ONYX FRONTIER, PAXLOVID, RESONATE EL ICD VR, Repatha, VYNDAQEL | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error